Skip to main content
Premium Trial:

Request an Annual Quote

Althea Technologies Spins out Molecular Dx Business

NEW YORK (GenomeWeb News) – Pharmaceutical services company Althea Technologies said yesterday it has spun out its molecular diagnostics and biomarker business into an independent company called Althea Diagnostics. 
 
The new company, which will be situated at Althea Technologies’ campus in San Diego, will commercialize a quantitative gene measurement technology and will seek to develop other tools and applications aimed at speeding up the development of molecular diagnostic tests.
 
Althea Diagnostics is developing a test for differential diagnosis of pediatric solid tumors along with other biomarker sets for use in cancer management.
 
Company Co-founder François Ferre said in a statement that the move to create a diagnostics-focused company was “a situation of technology and timing,” and said the attraction of the molecular diagnostics market was “too strong to resist.”
 
The spin-out also will continue to offer lab services to pharmaceutical companies and contract research organizations, including its Express Pathway suite, which is used to identify molecules, explore treatment pathways, and build sets of markers that may be of clinical utility.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.